Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-109200
Filing Date
2025-11-10
Accepted
2025-11-10 16:33:38
Documents
4
Period of Report
2025-12-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2529873d2_def14a.htm DEF 14A 107557
2 GRAPHIC tm2529873d1_pre14aimg001.jpg GRAPHIC 17129
3 GRAPHIC tm2529873d1_pre14aimg002.jpg GRAPHIC 126450
4 GRAPHIC tm2529873d1_pre14aimg003.jpg GRAPHIC 96782
  Complete submission text file 0001104659-25-109200.txt   432712
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12584 | Film No.: 251466821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)